Brought to you by 
Merck partners with Quartet Medicine in pain; gains option to buy company
15 Sep 2017
Executive Summary
Merck & Co. Inc. is partnering with translational medicine start-up Quartet Medicine Inc. to develop drugs for chronic pain from Quartet's pipeline of small-molecule compounds that modulate the tetrahydrobiopterin (BH4) pathway.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes M&A Option
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck partners with Quartet Medicine in pain; gains option to buy company
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice